This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rao, P. N. Articles by Raj, M. H. G. Search for Related Content PubMed PubMed Citation Articles by Rao, P. N. Articles by Raj, M. H. G.

Elevation of Serum Riboflavin Carrier Protein in Breast Cancer¹

Departments of Medicine [P. N. R., V. P., A. S., J. J. K., P. K.], Surgery [E. L., M. O. M., J. W.], Obstetrics and Gynecology [S. G. R., M. H. G. R.], and Biochemistry [M. H. G. R.], Louisiana State University Medical Center, New Orleans, Louisiana 70112

Presently available tumor markers have had a limited clinical impact. Riboflavin carrier protein (RCP) is an estrogen inducible protein that occupies a key position in riboflavin metabolism. Because other vitamin carrier proteins (VCP) have been shown to be overexpressed in patients with malignant disease, we evaluated serum RCP levels in patients with adenocarcinoma of the breast. In this prospective blinded study, patients with breast cancer, benign breast disease, and healthy controls were analyzed for RCP levels. Using a highly sensitive RIA, we observed that serum RCP levels were significantly elevated in women with breast cancer (n = 52) as compared with control subjects [n = 50; 6.06 ± 7.27 ng/ml versus 0.70 ± 0.19 ng/ml (mean ± SD), respectively; P < 0.0001]. A serum RCP level of 1.0 ng/ml was highly predictive of the presence of breast cancer, detecting 88% of tumors in stages I-II and 100% of tumors in stages III-IV. Overall, this RCP assay has a sensitivity of 92.3%, a specificity of 88%, a positive predictive value of 88.9%, and a negative predictive value of 91.7%. These results show increased serum levels of RCP in breast adenocarcinoma patients and suggest that RCP levels may be useful as a new marker for breast cancer. The positive predictive value in early-stage breast cancer suggests that the RCP assay may be a useful adjunct to present screening technology.

This article has been cited by other articles:

				A. B. Foraker, A. Ray, T. C. Da Silva, L. M. Bareford, K. M. Hillgren, T. D. Schmittgen, and P. W. Swaan Dynamin 2 Regulates Riboflavin Endocytosis in Human Placental Trophoblasts Mol. Pharmacol., September 1, 2007; 72(3): 553 - 562. [Abstract] [Full Text] [PDF]

				S. H. Taplin, L. Ichikawa, M. U. Yood, M. M. Manos, A. M. Geiger, S. Weinmann, J. Gilbert, J. Mouchawar, W. A. Leyden, R. Altaras, et al. Reason for Late-Stage Breast Cancer: Absence of Screening or Detection, or Breakdown in Follow-up? J Natl Cancer Inst, October 20, 2004; 96(20): 1518 - 1527. [Abstract] [Full Text] [PDF]